Wishing All The Best For The Coming Christmas And New Year 2023 Festive Season

Source: HydrUstent  Jul 03, 2018  4 years ago
HydrUStent’s Biodegradable Stents Could Improve Patient Outcomes
HydrUStent’s Biodegradable Stents Could Improve Patient Outcomes
Source: HydrUstent  Jul 03, 2018  4 years ago
Stents are widely used in patient care, but a major complication is infection and, for many types of stents, the need for eventual surgical removal. HydrUStent, a startup based at the University of Minho in Portugal, hopes to improve those limitations.
Patient Outcomes
HydrUStent’s product is a ureteral stent made from a patented material that is antibacterial, homogeneous, and biodegradable. It degrades by dissolution of the material in urine, which prevents the need for a second surgery for stent removal. “The dissolution profile is controlled and [depends] on the formulation used for stent production,” says CEO Alexandre Barros. Based on a patient’s specific needs, “the degradation rate in urine can be tuned from 15 to 60 days of
Biodegradable Stents
HydrUStent CEO Alexandre Barros

Timed degradation also helps prevent bacterial colonization and biofilm formation, according to Barros, which contribute to infection and are another complication of stents. “The major benefit for the payer is a reduction of 60% of the costs of the temporary stent treatment,” he says. “A second surgery is avoided and no more drug therapy is necessary after stent placement.”
The concept was originally envisioned in 2012 by Dr. Estevão Lima, the Director of the Urology Department at the Hospital de Braga in Portugal, which was developed with help from 3Bs Research Group, a Portuguese biomaterials research organization, directed by Prof. Rui L. Reis.
After the company was officially founded in 2016, the team has worked to validate the technology through several in vivo studies and now have a working prototype that has shown to be more biocompatible than commercially available ureteral stents. Currently, HydrUStent is working with medical device manufacturers in order to produce the device for use in humans.
“Our biggest goals are to have, in five years, three biodegradable medical device products” validated and in the market, says Barros. He notes that the company’s patented biodegradable materials could also be used in various devices that would otherwise require surgical removal—the ureteral stent is just the beginning.



Sep 08, 2022  3 months ago
Source- Medical News - COVID-19 Research - Impaired Pain Modulation
Aug 13, 2020  2 years ago
Source: Supplements For COVID-19
Feb 05, 2020  3 years ago
Source : Thailand Medical news